ClinicalTrials.gg
Not yet recruitingNCT06982547Updated May 21, 2025

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

An Early Phase 1 interventional study of UTAA91 injection in Rheumatoid Arthritis (RA), sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
185th of 217
24 · median 134
Started
2025
with 34 others
Phase 1
54 of 249
20 open now
Primary completion
2027-12
later than 49 of 71 live
Registered
207th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 185th largest by planned enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 54 in phase 1, reaches primary completion later than 49 of the 71 other live ones, and was the 207th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.
  • Expected survival time of at least 3 months.
  • Subjects with moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options.
  • Meet the requirements for liver and kidney function, as well as cardiopulmonary function.
  • Free from severe psychiatric disorders.
  • Able to understand the trial and have signed the form.

Exclusion criteria

Exclusion Criteria:

  • A history of malignant tumors other than diseases (R/R AID) within 5 years prior to screening.
  • Subjects with positive results in virus/syphilis tests.
  • Severe cardiac diseases or unstable systemic diseases.
  • Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening.
  • Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.
  • Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening.
  • Subjects who participated in other clinical studies within 1 month before screening.
  • Other conditions deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    UTAA91 injection

    Biological: UTAA91 injection

Interventions

  • After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.

06

What researchers measure

Primary outcomes

  1. Adverse events

    The types, frequency, and severity of adverse events (AEs) and laboratory abnormalities (according to the Common Terminology Criteria for Adverse Events, NCI CTCAE 5.0).

    Time frame: About 1 year

Secondary outcomes

  1. Cmax

    Maximum concentration of UTAA91 injection amplified in peripheral blood after administration of the drug

    Time frame: About 1 year

  2. Tmax

    Time to reach maximum concentration in peripheral blood after administration of UTAA91 injection

    Time frame: About 1 year

  3. Disease remission rate

    The disease remission/response/improvement rates at 28 days, 2 months, and 3 months after treatment with UTAA91 injection.

    Time frame: About 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2027, 30 months later.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 30 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 21, 2025
StartEst.
Jun 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2040
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06982547
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Jun 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jun 2040 (estimated)
Last update
May 21, 2025

Study contacts

Qiubai Li, MD
Contact
qiubaili@hust.edu.cn
+86-13995671635

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UTAA91

Start the discussion